Trial · NCT01717313
Adverse events38
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 38
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Omarigliptin | 17 | 165 | 21 |
| other | Nasopharyngitis | Infections and infestations | Placebo to Omarigliptin | 12 | 164 | 16 |
| other | Blood glucose increased | Investigations | Omarigliptin | 14 | 165 | 14 |
| other | Blood glucose increased | Investigations | Placebo to Omarigliptin | 13 | 164 | 13 |
| serious | Acute myocardial infarction | Cardiac disorders | Omarigliptin | 0 | 165 | 0 |
| serious | Acute myocardial infarction | Cardiac disorders | Placebo to Omarigliptin | 1 | 164 | 1 |
| serious | Cataract | Eye disorders | Omarigliptin | 0 | 165 | 0 |
| serious | Cataract | Eye disorders | Placebo to Omarigliptin | 1 | 164 | 1 |
| serious | Pneumonia | Infections and infestations | Omarigliptin | 1 | 165 | 1 |
| serious | Pneumonia | Infections and infestations | Placebo to Omarigliptin | 0 | 164 | 0 |
| serious | Tendon rupture | Injury, poisoning and procedural complications | Omarigliptin | 1 | 165 | 1 |
| serious | Tendon rupture | Injury, poisoning and procedural complications | Placebo to Omarigliptin | 0 | 164 | 0 |
| serious | Vulval cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Omarigliptin | 0 | 165 | 0 |
| serious | Vulval cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo to Omarigliptin | 1 | 164 | 1 |
| serious | Calculus ureteric | Renal and urinary disorders | Omarigliptin | 0 | 165 | 0 |
| serious | Calculus ureteric | Renal and urinary disorders | Placebo to Omarigliptin | 2 | 164 | 2 |
| serious | Urethral stenosis | Renal and urinary disorders | Omarigliptin | 1 | 165 | 1 |
| serious | Urethral stenosis | Renal and urinary disorders | Placebo to Omarigliptin | 0 | 164 | 0 |
| serious | Hypertension | Vascular disorders | Omarigliptin | 1 | 165 | 1 |
| serious | Hypertension | Vascular disorders | Placebo to Omarigliptin | 0 | 164 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01717313/events